Key facts
- Kalshi will launch new prediction markets focused on clinical trial outcomes and FDA regulatory decisions.
- The platform is partnering with AI firm AppliedXL for this expansion.
- Trading will be restricted to late-stage trials, with contracts listed after enrollment completion.
- Employment verification will be required to trade, and individuals with material nonpublic information will be prohibited.
- The initiative aims to provide public probabilities for drug development processes.
Prediction market platform Kalshi is expanding its offerings to include trading on the outcomes of clinical trials and U.S. Food and Drug Administration (FDA) regulatory decisions. This move, developed in partnership with AI firm AppliedXL, aims to make drug development probabilities publicly accessible.
Kalshi CEO Tarek Mansour stated that drug development is an information-constrained industry and that the platform seeks to surface data that is otherwise locked away. The new markets will focus on late-stage trials, with contracts listed only after enrollment is complete. Trading criteria will be based on publicly available documents like trial endpoints and FDA approval letters.
Critics have voiced concerns about the potential for market manipulation and insider trading on such platforms. In response, Kalshi will implement employment verification and prohibit trading by individuals with material nonpublic information. The company also plans to restrict trading to late-stage trials to avoid interfering with recruitment.
This expansion follows Kalshi's previous plans to offer contracts on flight cancellations, a venture that was reportedly paused after concerns arose about potential disruptions. The company has seen significant trading volume and user growth, though experts note the addictive nature of prediction markets. Kalshi has committed funds to the National Council on Problem Gambling.